MedPage Today - "Analysis: Few Surprises with New MS Drugs" - John Gever
Aaron Miller, MD, of the Icahn School of Medicine at Mount Sinai, presented the highlight presentation on the drug teriflunomide for multiple sclerosis at last week’s American Academy of Neurology (AAN) meeting in San Diego. Dr. Miller reported that a lower dose of the teriflunomide produced a 22.3% reduction in mean annualized relapse rate, with a 36.3% reduction in the high-dose group. The lower dose was no better than placebo in delaying disability progression. Patients on the higher dose showed a small improvement in disability.